文献速递耳科与耳神经小儿耳鼻咽喉

环丙沙星联合氟轻松治疗儿童鼓膜置管后中耳炎的疗效与安全性:一项随机临床试验

Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2017-01-01

两项设计相同的多中心随机双盲试验纳入662例鼓膜置管后中耳炎伴化脓性耳漏患儿,比较环丙沙星联合氟轻松、单用环丙沙星及单用氟轻松的疗效与安全性。联合组耳漏停止中位时间4.23天,短于单用环丙沙星组的6.95天(P<.001);联合组治愈访视临床治愈率80.6%,高于单用环丙沙星组67.4%和单用氟轻松组47.6%。

要点

  • 联合组耳漏停止中位时间4.23天,短于单用环丙沙星组6.95天(P<.001)。
  • 治愈访视联合组临床治愈率80.6%,高于单用环丙沙星组67.4%和单用氟轻松组47.6%。
  • 联合组持续微生物学治愈率79.7%,高于单用环丙沙星组67.7%和单用氟轻松组37.6%。

核心结论

  • 环丙沙星联合氟轻松治疗儿童鼓膜置管后中耳炎比单用环丙沙星或单用氟轻松更有效,且安全、耐受良好。

研究设计与样本

  • 两项设计相同的多中心随机双盲临床试验,于2011年6月24日至2014年6月23日在耳鼻咽喉科儿科诊所、全科诊所、医院和临床研究中心开展。
  • 共纳入662例(每项试验331例)至少1耳鼓膜置管后中耳炎、伴中度或重度化脓性耳漏持续3周或以内的儿童,按意向治疗分析。
  • 患者随机接受环丙沙星联合氟轻松、单用环丙沙星或单用氟轻松,每日两次,持续7天,并于第1天(基线)、第3至5天(治疗中)、第8至10天(治疗结束)和第18至22天(治愈访视)评估。

主要发现

  • 662例患儿随机分至环丙沙星联合氟轻松组(n=223)、单用环丙沙星组(n=221)或单用氟轻松组(n=218),中位年龄2.5岁(范围0.6-12.7岁)。
  • 耳漏停止中位时间:联合组4.23天(95%CI 3.65-4.95天)vs 单用环丙沙星组6.95天(95%CI 5.66-8.20天),单用氟轻松组不可估计(P<.001)。
  • 治愈访视临床治愈率:联合组80.6% vs 单用环丙沙星组67.4%(差值13.2%,95%CI 5.0%-21.4%;P=.002)vs 单用氟轻松组47.6%(差值33.0%,95%CI 24.0%-42.0%;P<.001)。
  • 持续微生物学治愈率:联合组79.7% vs 单用环丙沙星组67.7%(差值12.0%,95%CI 0.8%-23.0%;P=.04)vs 单用氟轻松组37.6%(差值42.1%,95%CI 29.3%-54.8%;P<.001)。
  • 与研究药物相关的不良事件:联合组7例(3.1%),单用环丙沙星组8例(3.6%),单用氟轻松组10例(4.7%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Acute otitis media with tympanostomy tubes (AOMT) in children commonly presents with otorrhea and negatively affects their daily activities. OBJECTIVE: To evaluate the efficacy and safety of topical ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution relative to ciprofloxacin, 0.3%, otic solution alone and fluocinolone acetonide, 0.025%, otic solution alone in the treatment of AOMT in children. DESIGN, SETTING, AND PARTICIPANTS: Two twin multicenter, randomized, double-blind clinical trials with identical designs were conducted from June 24, 2011, through June 23, 2014, at ear, nose, and throat pediatric practices, general practices, hospitals, and clinical research centers. The study population comprised 662 children (331 in each trial) with AOMT in at least 1 ear who presented with moderate or severe purulent otorrhea for 3 weeks or less. Data analyses were performed on an intention-to-treat basis. INTERVENTIONS: Patients were randomly assigned to receive ciprofloxacin plus fluocinolone, ciprofloxacin alone, or fluocinolone alone twice daily for 7 days and were evaluated on days 1 (baseline), 3 to 5 (undergoing therapy), 8 to 10 (end of therapy), and 18 to 22 (test of cure). MAIN OUTCOMES AND MEASURES: The primary efficacy measure was time to cessation of otorrhea. The principal secondary end point was sustained microbiological cure, defined as eradication or presumed eradication at end-of-therapy and test-of-cure visits. RESULTS: A total of 662 children participating in the 2 studies were randomized to receive ciprofloxacin plus fluocinolone (n = 223), ciprofloxacin alone (n = 221), or fluocinolone alone (n = 218). The median age was 2.5 years (range, 0.6-12.7 years). The median time to cessation of otorrhea was 4.23 days (95% CI, 3.65-4.95 days) in patients receiving ciprofloxacin plus fluocinolone compared with 6.95 days (95% CI, 5.66-8.20 days) in those receiving ciprofloxacin and not estimable findings in those receiving fluocinolone alone (P < .001). The clinical cure rate at the test-of-cure visit was 80.6% in the ciprofloxacin plus fluocinolone group, 67.4% in the ciprofloxacin group (difference, 13.2%; 95% CI, 5.0%-21.4%; P = .002), and 47.6% in the fluocinolone group (difference, 33.0%; 95% CI, 24.0%-42.0%; P < .001). The sustained microbiological cure rate was 79.7% in the ciprofloxacin plus fluocinolone group vs 67.7% in the ciprofloxacin group (difference, 12.0%; 95% CI, 0.8%-23.0%; P = .04) and 37.6% in the fluocinolone group (difference, 42.1%; 95% CI, 29.3%-54.8%; P < .001). Only 7 (3.1%) of the patients receiving ciprofloxacin plus fluocinolone, 8 (3.6%) of the patients receiving ciprofloxacin, and 10 (4.7%) of the patients receiving fluocinolone presented with adverse events related to study medication. CONCLUSIONS AND RELEVANCE: The combination of ciprofloxacin plus fluocinolone is more effective than treatment with ciprofloxacin or fluocinolone alone for AOMT, and it is safe and well tolerated in children. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT01395966 and NCT01404611.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Spektor Z, Pumarola F, Ismail K, et al. Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 28006041. doi:10.1001/jamaoto.2016.3537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。